Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
Ford Targets Level 3 Autonomous Driving by 2028 with New EV Platform and AI Innovations 
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
NEW YORK, March 17, 2017 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Galena Biopharma, Inc. securities (NASDAQ:GALE) from August 11, 2014 through January 31, 2017, both dates inclusive (the “Class Period”) of the April 14, 2017 lead plaintiff deadline in the class action first filed by Rosen Law Firm. This first filed lawsuit seeks to recover damages for Galena investors under the federal securities laws.
To join the Galena class action, go to http://www.rosenlegal.com/cases-1054.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Galena’s sales of Abstral were based on unsustainable sales and marketing practices; (2) such sales and marketing practices could subject Galena to a criminal investigation; and (3) as a result, Defendants’ statements about Galena’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 14, 2017. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-1054.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com
